Choice of modelling technique for evaluating health care interventions

Journal of the Operational Research Society

Volumn 58, Issue 2, 2007, Pages 168-176

  Cooper, K ^a,c   Brailsford, S C ^a   Davies, R ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cost effectiveness; Decision tree; Discrete event simulation; Health care; Markov; Model

Indexed keywords

COST EFFECTIVENESS; DECISION MAKING; MARKOV PROCESSES; MATHEMATICAL MODELS; QUEUEING THEORY;

DECISION TREES; DISCRETE EVENT SIMULATION; MODEL SIZE; RESOURCE CONSTRAINTS;

HEALTH CARE;

EID: 33846889006     PISSN: 01605682     EISSN: 14769360     Source Type: Journal    
DOI: 10.1057/palgrave.jors.2602230     Document Type: Conference Paper

References (54)

1. Adams ME et al (1992). Economic analysis in randomized control trials. Med Care 30: 231-243.
2. Akehurst R et al (2000). Decision analytic modelling in the economic evaluation of health technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment. Pharmacoeconomics 17: 443-444.
3. Babad H et al (2002). The development of a simulation model of primary prevention strategies for coronary heart disease. Health Care Mngt Sci 5: 269-274.
4. Barton P, Bryan S and Robinson S (2004). Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy 9: 110-118.
5. Briggs A and Sculpher M (1995). Sensitivity analysis in economic evaluation: a review of published studies. Health Econ 4: 355-371.
6. Briggs A, Sculpher M and Buxton M (1994). Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 3: 95-104.
7. Briggs AH (2000). Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17: 479-500.
8. Caro JJ (2005). Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 23: 323-332.
9. Chase D et al (2006). Using simulation to estimate the cost effectiveness of improving ambulance and thrombolysis response times after myocardial infarction. Emerg Med J 23: 67-72.
10. Claxton K et al (2005). Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 14: 339-347.
11. Cooper K (2005). A comparative study of modelling approaches for the evaluation of healthcare interventions with reference to Coronary Heart Disease. PhD Thesis (unpublished), University of Southampton.
12. Cooper K, Brailsford SC, Davies R and Raftery J (2006). A Review of Health Care Models for Coronary Heart Disease Interventions. Health Care Mngt Sci 9 (in press).
13. Cooper K et al (2002). The development of a simulation model of the treatment of coronary heart disease. Health Care Mngt Sci 5: 259-267.
14. Davies HTO and Davies R (1995). Simulating health systems: modelling problems and software solutions. Eur J Opns Res 87: 35-44.
15. Davies R et al (2000). Using simulation modelling for evaluating screening services for diabetic retinopathy. J Opl Res Soc 51: 476-484.
16. Davies R and Davies HTO (1994). Modelling patient Hows and resource provision in health systems. Omega Int J Mngt Sci 22: 123-131.
17. Davies R, Roderick P and Raftery J (2003). The evaluation of disease prevention and treatment using simulation models. Eur J Opns Res 53-66.
18. Drummond MF and Jefferson TO (1996). Guidelines for authors and peer reviewers of economic submissions to the BM.I. The BMJ Economic Evaluation Working Party. BMJ 313: 275-283.
19. Elixhauser A, Halpern M, Schmier J and Luce BR (1998). Health care CBA and CEA from 1991 to 1996: an updated bibliography. Med Care 36: MS1-147.
20. Elixhauser A, Luce BR, Taylor WR and Reblando J (1993). Health care CBA/CEA: an update on the growth and composition of the literature. Med Care 31: JS1-149.
21. Evans C, Tavakoli M and Crawford B (2004). Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal. Health Care Mngt Sci 7: 43-49.
22. Evans RG (1995). Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med 123: 59-60.
23. Fone D et al (2003). Systematic review of the use and value of computer simulation modelling in population health and health care delivery. J Public Health Med 25: 325-335.
24. Gerard K, Seymour J and Smoker 1 (2000). A tool to improve quality of reporting published economic analyses. Int J Technol Assess Health Care 16: 100-110.
25. Halpern MT, Luce BR, Brown RE and Geneste B (1998). Health and economic outcomes modeling practices: a suggested framework. Value in Health 1: 131-147.
26. Jefferson T and Demicheli V (1994). Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 3: 25-37.
27. Jefferson T, Demicheli V and Vale L (2002). Quality of systematic reviews of economic evaluations in health care. JAMA 287: 2809-2812.
28. Jun JB, Jacobson SH and Swisher JR (1999). Application of discreteevent simulation in health care clinics: A survey. J Opl Res Soc 50: 109-123.
29. Karnon J (2003). Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ 12: 837-848.
30. Karnon J and Brown J (1998). Selecting a decision model for economic evaluation: a case study and review. Health Care Mngt Sci 1: 133-140.
31. Luce BR, Lyles CA and Rentz AM (1996). The view from managed care pharmacy. Health Aff (Millwood) 15: 168-176.
32. Mauskopf J (1998). Prevalence based economic evaluation. Value in Health 1: 251-259.
33. Melao N and Pidd M (2003). Use of business process simulation: a survey of practitioners. J Opl Res Soc 54: 2-10.
34. National Institute for Clinical Excellence (2004). Guide to the methods of technology appraisal. NICE: London.
35. Neumann PJ et al (2000). The quality of reporting in published costutility analyses, 1976-1997. Ann Intern Med 132: 964-972.
36. Neumann PJ, Zinner DE and Wright JC (1997). Are methods for estimating QALYs in cost-effectiveness analyses improving? Med Decis Making 17: 402-408.
37. Philips Z et al (2004). Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 8: iii-xi, 1.
38. Pickin DM et al (1999). Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 82: 325-332.
39. Robinson S (2003). Simulation: The Practice of Model Development and Use. John Wiley and Sons Ltd: Chichester, UK.
40. Russell LB et al (1996). The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1172-1177.
41. Sculpher M, Fenwick E and Claxton K (2000). Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application. Pharmacoeconomics 17: 461-477.
42. Siegel JE, Weinstein MC, Russell LB and Gold MR (1996). Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA 276: 1339-1341.
43. Sonnenberg FA and Beck JR (1993). Markov models in medical decision making: a practical guide. Med Decis Making 13: 322-338.
44. Sonnenberg FA et al (1994). Toward a peer review process for medical decision analysis models. Med Care 32: JS52-JS64.
45. Tappenden P et al (2004). Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-bcta and glatiramer acetate for multiple sclerosis. Health Technol Assess 8: iii, 1-iii, 78.
46. Thomas LC, McKinnon KIM and Archibald TW (1995). A portfolio of purchase contracts-an example of solving large-scale dynamic programming on parallel computers. IMA J Math Appl Bus Ind 6: 193-204.
47. Torrance GW and Feeny D (1989). Utilities and quality-adjusted life years. Int J Technol Assess Health Care 5: 559-575.
48. Udvarhelyi IS, Colditz GA, Rai A and Epstein AM (1992). Costeffectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly? Ann Intern Med 116: 238-244.
49. Weinstein MC (1989). Methodologie issues in policy modeling for cardiovascular disease. J Am Coll Cardiol 14: 38A-43A.
50. Weinstein MC et al (1987). Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 77: 1417-1426.
51. Weinstein MC et al (2003). Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health 6: 9-17.
52. Weinstein MC et al (1996). Recommendations of the Panel on Costeffectiveness in Health and Medicine. JAMA 276: 1253-1258.
53. Xie H, Chaussalet TJ and Millard RH (2005). A continuous time Markov model for the length of stay of elderly people in institutional long-term care. J R Stat Soc Ser A-Stat Soc 168: 51-61.
54. Yock CA et al (2003). Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Med 115: 382-389.